
    
      Immunity to melanoma appears to be central to disease control in the adjuvant and advanced
      disease settings. Spontaneous regression has been reported in melanoma, suggesting a role for
      host immunity, indirectly supported by the presence of lymphoid infiltrates at primary
      melanoma associated with tumor regression.
    
  